Synopsis: Ace investor Vijay Kishanlal Kedia acquired a fresh 0.87% stake in Mangalam Drugs and Organics by purchasing 1.38 lakh equity shares through a bulk deal, highlighting growing investor confidence in the company.
This Penny Pharma Stock Under Rs. 30, engaged in manufacturing active pharmaceutical ingredients, anti-malarial APIs and intermediates at manufacturing facilities in Gujarat and Maharashtra, hit a 5 percent upper circuit after Vijay Kishanlal Kedia made a fresh stake of 0.87 percent in the company.
With a market capitalization of Rs. 41.60 crores, the shares of Mangalam Drugs and Organics Limited hit a 5 percent upper circuit of Rs.26.28 per share on Tuesday, up from its previous closing price of Rs. 25.03 per share.
Reason Behind the Surge:
Ace investor Vijay Kishanlal Kedia made a notable investment in Mangalam Drugs and Organics Ltd through a bulk deal on December 29, 2025. His firm, Kedia Securities Private Limited, purchased 1,37,794 shares at an average price of Rs. 24.15 per share. This bulk transaction amounts to a total deal value of approximately Rs. 33.28 lakh, reflecting continued investor interest in the company.
Mangalam Drugs and Organics Limited had a majority stake held by the promoters at 50.30 percent, foreign institutional investors at 0.11 percent, and the public at 49.57 percent in September 2025. Ace investor Vijay Kishanlal Kedia has bought a fresh stake of approximately 0.87 percent of Mangalam Drugs and Organics Limited.
Company Overview:
Mangalam Drugs and Organics Limited was established in 1977 and manufactures active pharmaceutical ingredients (APIs) and intermediates at manufacturing facilities in Vapi, Gujarat, and Sangamner, Maharashtra.
The company began as a producer of organic and inorganic chemicals and evolved into a key player in anti-malarial drugs, earning global recognition through WHO approvals and partnerships like the Clinton Health Access Initiative.
Mangalam Drugs and Organics Limited is supported by over 50 experienced scientists, more than 579 advanced pieces of equipment, and deep capabilities built on more than 342 field and industry expertise areas, enabling high-quality API manufacturing and innovation.
Products and Services:
Mangalam Drugs and Organics Limited specializes in frontline anti-malaria APIs such as artemether, artesunate, lumefantrine, and chloroquine phosphate, alongside diversified products including acyclovir, hydroxychloroquine, efavirenz, and tenofovir variants.
The company also produces intermediates and bulk drugs for formulations, supported by an in-house DSIR-recognized R&D lab. Mangalam Drugs and Organics Limited holds certifications like WHO-GMP, EDQM, and ANVISA, positioning it as a top Asian producer of anti-malarial APIs and diversified pharmaceuticals.
Recent Quarter Results:
Coming into financial highlights, Mangalam Drugs and Organics Limited’s revenue has decreased from Rs. 79.94 crore in Q2 FY25 to Rs. 49.54 crore in Q2 FY26, which is a drop of 38.03 percent. The net profit of the company converted from positive to negative, from a net profit of Rs. 2.69 crore in Q2 FY25 to a net loss of Rs. 7.35 crore in Q2 FY26.
In terms of return ratios, the company’s ROCE and ROE stand at 8.05 percent and 4.68 percent, respectively. Mangalam Drugs and Organics Limited has an earnings per share (EPS) of Rs. -12.5, and its debt-to-equity ratio is 0.74x.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
